California’s new Consumer Privacy Act (AB 375), the toughest data privacy law in the nation, will impose stringent new requirements on the state’s high-profile tech companies in 2020. Its impacts on the life sciences industry, though, remain unclear. CLSA’s State Government Relations team sat down with BioWorld to discuss what the measure means for innovative biomedical companies.
CLSA’s Weekly Sacramento At-A Glance Newsletter provides our membership with the latest happenings for the life sciences sector in the California State Government.
On Friday, July 13, California’s Office of Statewide Health Planning and Development (OSHPD) posted for public comment (available here) its official rulemaking package for implementing Senate Bill 17 in California.
California’s Proposition 65 requires businesses to provide warnings with products or at facilities if they contain any chemicals (out of a list of around 900) at levels above specified safe harbor levels.
According to Kaiser Health News, patients overpay for prescriptions 23% of the time. Check out CLSA’s infographic calling for more accountability of Pharmacy Benefit Managers (PBMs).
The California Legislature voted to approve a budget deal on June 14 between Democratic legislators and Governor Jerry Brown, which will be his last budget as governor. The budget was passed hours prior to the June 15 at midnight deadline, includes several significant wins for the life sciences sector.
As results from yesterday’s California Primary Elections continue trickling in, CLSA’s state government relations team would like to share a brief update on some anticipated changes in the makeup of the California Legislature, and offer additional details on several key California races you may be interested in.
Despite media and policymaker scrutiny over the cost of prescription drugs, the healthcare companies making the most money are not biopharmaceutical innovators. Check out CLSA’s infographic calling for more accountability of Pharmacy Benefit Managers (PBMs).
CLSA is excited to launch a new video series to tell the stories of California patients whose lives have been positively impacted by the California life sciences sector.
Despite California’s significant budget surplus, legislators are continuing to propose burdensome taxes affecting the life sciences industry, among many others. The two tax bills most recently raising alarms among CLSA staff and membership are Senate Bill 993 (Hertzberg) and Assembly Bill 2731 (Gipson).